Compare OPRX & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | YARW |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | 105 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 154.5M |
| IPO Year | 2008 | 2017 |
| Metric | OPRX | YARW |
|---|---|---|
| Price | $7.68 | $18.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $12.30 | ★ $57.33 |
| AVG Volume (30 Days) | ★ 181.3K | 173.9K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $12.39 |
| 52 Week High | $15.59 | $44.28 |
| Indicator | OPRX | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 48.63 |
| Support Level | $7.23 | $18.05 |
| Resistance Level | $8.30 | $20.57 |
| Average True Range (ATR) | 0.69 | 2.44 |
| MACD | -0.19 | 0.46 |
| Stochastic Oscillator | 38.21 | 77.19 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.